Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
The mechanism of the flavin reductase process is described above and most likely follows the ping pong kinetic pattern. This means that it is a bisubstrate-biproduct mechanism. First the flavin reductase enzyme binds NADPH and stabilizes the release of the hydride. Because of sterics, it is not possible for the enzyme to bind both NADPH and the flavin. For this reason, NADP+ is released and then the flavin substrate is bound to the enzyme. In this step, the hydride attacks Nitrogen on the flavin, which allows for another protonation. Then, reduced flavin is released from flavin reductase as the second product. In this way, the reduction of flavin is dependent on flavin reductase binding first to NADPH, or in some cases NADH.
transcriptomics The study of the transcriptome of a particular genome, cell, or organism, i.e. the sum total of all of the RNA transcripts produced from it by transcription. Transcriptomics technologies allow scientists to isolate and sequence transcriptomes, which can then be mapped to the genome to determine which genes are being expressed or which cellular processes are active and which are dormant at a given time.
While electronic review later indicated the serve was out, Roland Garros does not use Hawk-Eye as an official officiating tool; instead, the technology is used exclusively for television broadcasts. It is noted that the broadcast version of Hawk-Eye operates with significantly lower precision than the official Electronic Line Calling (ELC) systems installed at other tournaments, leaving open the possibility that the umpire's ruling on the clay mark was accurate. However, the overrule generated controversy. Had the call not been overturned, Zverev would have broken back. Tennis commentator Robbie Koenig and former world No. 1 Andy Roddick disagreed with the overrule. Zverev would go on to lose the fifth set, giving up his two-sets-to-one lead and finishing runner-up to Carlos Alcaraz, who collected his maiden French Open title. In Halle, Zverev reached the semifinals after collecting wins against Oscar Otte, Lorenzo Sonego, and Arthur Fils, losing to Hubert Hurkacz in straight sets. At Wimbledon, Zverev beat Roberto Carballés Baena, Marcos Giron, and Cameron Norrie before losing to Taylor Fritz in the fourth round. His third-set tiebreak with Norrie was noted as one of the longest tiebreaks of the tournament, with Zverev prevailing 17–15 after 26 minutes. Back on clay, Zverev reached the final in Hamburg, losing to Arthur Fils in three sets. At the Olympic Games in Paris, Zverev represented Team Germany as defending champion.
Cossack relations with the Tsardom of Russia were varied from the outset. At times they supported Russian military operations, at other times they rebelled against the central power. After one such uprising at the end of the 18th century, Russian forces destroyed the Zaporozhian Host. Many of the Cossacks who had remained loyal to the Russian Monarch and continued their service later moved to the Kuban. Others, choosing to continue a mercenary role, escaped control in the large Danube Delta. The service of the Cossacks in the Napoleonic wars led them to be celebrated as Russian folk heroes, and throughout the 19th century a "powerful myth" was promoted by the government that portrayed the Cossacks as having a special and unique bond to the Emperor. This image of the Cossacks as ultra-patriotic defenders of not only Russia, but also of the House of Romanov was embraced by many ordinary Cossacks, making them into a force for conservatism. By the 19th century, the Russian Empire had annexed the territory of the Cossack Hosts, and controlled them by providing privileges for their service such as exemption from taxation and allowing them to own the land they farmed. At this time, the Cossacks served as military forces in many wars conducted by the Russian Empire. Cossacks were considered excellent for scouting and reconnaissance duties, and for ambushes. Their tactics in open battle were generally inferior to those of regular soldiers, such as the Dragoons.
== Clinical significance == Maleylacetoacetate isomerase deficiency is a disease caused by a mutation in the gene GSTZ1. This is an autosomal recessive inborn error of metabolism. It is caused by a mutation in the gene that codes for the synthesis of 4-maleylacetoacetate isomerase, GSTZ1. Mutations in 4-maleylacetoacetate isomerase resulted in accumulation of fumarylacetoacetate and succinylacetone in the urine, but individuals were otherwise healthy. It is likely that there exists an alternate nonenzymatic bypass that allows the catabolism of 4-maleylacetoacetate in the absence of 4-maleylacetoacetate isomerase. Because of this mechanism, a mutation in the gene encoding 4-Maleylacetoacetate isomerase is not considered dangerous. GSTZ1 is highly expressed in the liver, however mutations in this gene do not impair liver function or coagulation.
Sources: en.wikipedia.org
=== Condensed matter and macromolecules === Metastable phases are common in condensed matter and crystallography. This is the case for anatase, a metastable polymorph of titanium dioxide, which despite commonly being the first phase to form in many synthesis processes due to its lower surface energy, is always metastable, with rutile being the most stable phase at all temperatures and pressures. As another example, diamond is a stable phase only at very high pressures, but is a metastable form of carbon at standard temperature and pressure. It can be converted to graphite (plus leftover kinetic energy), but only after overcoming an activation energy – an intervening hill. Martensite is a metastable phase used to control the hardness of most steel. Metastable polymorphs of silica are commonly observed. In some cases, such as in the allotropes of solid boron, acquiring a sample of the stable phase is difficult. The bonds between the building blocks of polymers such as DNA, RNA, and proteins are also metastable. Adenosine triphosphate (ATP) is a highly metastable molecule, colloquially described as being "full of energy" that can be used in many ways in biology. Generally speaking, emulsions/colloidal systems and glasses are metastable. The metastability of silica glass, for example, is characterised by lifetimes on the order of 1098 years (as compared with the lifetime of the universe, which is thought to be around 1.3787×1010 years). Sandpiles are one system which can exhibit metastability if a steep slope or tunnel is present. Sand grains form a pile due to friction.
. From here, one might attempt to solve the Schrödinger equation for this Hamiltonian directly in its current form. However, it proves far more analytically bountiful to take advantage of the fact that this system is actually isomorphic to three uncoupled harmonic oscillators. One need only define the ladder operators
Levonantradol (CP 50,556-1) is a synthetic cannabinoid analog of dronabinol (Marinol) developed by Pfizer in the 1980s. It is around 30 times more potent than THC, and exhibits antiemetic and analgesic effects via activation of CB1 and CB2 cannabinoid receptors. Levonantradol is not currently used in medicine as dronabinol or nabilone are felt to be more useful for most conditions, however it is widely used in research into the potential therapeutic applications of cannabinoids.
23 July – The World Health Organization (WHO) declares the recent monkeypox outbreak a Public Health Emergency of International Concern, as the number of reported cases worldwide exceeds 17,000. In July, scientists reported that the window to be able to contain the outbreak is closing or has closed. On 5 July, a preprint indicates there can be asymptomatic infections. On 27 July, an analysis of studies by a journalist indicates that "about 10-to-15% of cases have been hospitalized, mostly for pain and bacterial infections that can occur as a result of monkeypox lesions". Studies published in August indicated hospitalizations of small cohorts of early patients were 8% and 13%. 25 July Researchers introduce the concept of necrobotics and demonstrate it by repurposing dead spiders as robotic grippers by activating their gripping arms via applying pressurized air. Researchers review the scientific literature on 100% renewable energy, addressing various issues, outlining open research questions, and concluding there to be growing consensus, research and empirical evidence concerning its feasibility worldwide. 26 July – Scientists analyse 2.8 million of the sequenced SARS-CoV-2 genomes and use the results to compile a 'mutations blacklist' of virus weak spots, and a 'whitelist' of mutations that would make it more transmissible. 27 July – Progress towards a pan coronavirus vaccine is announced, following tests on mice. Antibodies targeting the S2 subunit of SARS-CoV-2's spike protein are found to neutralise multiple coronavirus variants.
HPTLC has also been used successfully in the separation of various lipid subclasses, with reproducible and promising results obtained for 20 different lipid subclasses. Numerous reports related to clinical medicine studies have been published in various journals. As a result, HPTLC is now strongly recommended for drug analysis in serum and other tissues.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.